Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Original Article

Volume 11, Number 4, April 2019, pages 256-260


Long-Term Efficacy, Safety, and Tolerability of Modified Intravesical Oxybutynin Chloride for Neurogenic Bladder in Children

Figure

Figure 1.
Figure 1. Cystometrograms of patient 1 before and after treatment.

Tables

Table 1. Patient Profiles
 
PatientAgeSexDisease
y: years; m: months.
13y7mMalePelvic teratoma
21y6mMaleMyelomeningocele
31y6mFemaleMyelomeningocele
42y5mMaleMyelomeningocele

 

Table 2. Bladder Compliance, Detrusor Overactivity and Urinary Incontinence Before and After Treatment
 
PatientBladder compliance (cm H2O/mL)Detrusor overactivityUrinary incontinence
Before1 y later3 y later10 y laterBefore1 y later3 y later10 y laterBefore1 y later3 y later10 y later
y: years; m: month; d: day; NP: not performed. aat 118 months.
11.76.76.53.7a+++a3 times/mNoneNone2.3 times/da
20.23.54.710.5+4.6 times/d3 times/mNoneNone
30.110.09.39.7+NoneNoneNoneNone
42.5NP5.911.8+NP4.5 times/dNoneNoneNone

 

Table 3. Incidence of UTIs
 
Patient1 y before instituting treatment1 y after instituting treatment3 y after instituting treatment10 y after instituting treatment
UTI: urinary tract infection; ABU: asymptomatic bacteriuria. aat 118 months.
1Lower UTI (3 times)NoneNoneUpper UTI (2 times)a
2ABUABUNoneNone
3ABUNoneNoneNone
4ABUABUABUABU